These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 2910297)

  • 1. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.
    Schott B; Robert J
    Biochem Pharmacol; 1989 Jan; 38(1):167-72. PubMed ID: 2910297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel
    van Gelder MA; Li Y; Wander DPA; Berlin I; Overkleeft HS; van der Zanden SY; Neefjes JJC
    J Med Chem; 2024 Aug; 67(16):13802-13812. PubMed ID: 39088428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme.
    Turek A; Stoklosa K; Borecka A; Paul-Samojedny M; Kaczmarczyk B; Marcinkowski A; Kasperczyk J
    Pharm Res; 2020 May; 37(5):90. PubMed ID: 32382838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma.
    Chehimi M; Boone M; Chivot C; Deramond H; Constans JM; Ly MC; Chauffert B
    Case Rep Oncol; 2016; 9(2):499-505. PubMed ID: 27721775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain Tumor Genetic Modification Yields Increased Resistance to Paclitaxel in Physical Confinement.
    Bui L; Hendricks A; Wright J; Chuong CJ; Davé D; Bachoo R; Kim YT
    Sci Rep; 2016 May; 6():26134. PubMed ID: 27184621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
    Recinos VR; Bekelis K; Ziegler SG; Vick D; Hertig S; Tyler BM; Li KW; Kosztowski T; Legnani FG; Brem H; Olivi A
    J Neurooncol; 2010 Mar; 97(1):1-10. PubMed ID: 19693439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
    Corsini C; Ghielmini M; Mancuso P; Tealdo F; Paolucci M; Zucchetti M; Ferrucci PF; Cocorocchio E; Mezzetti M; Mori A; Riggi M; D'Incalci M; Martinelli G
    Br J Cancer; 2000 Feb; 82(3):524-8. PubMed ID: 10682659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
    Kaaijk P; Troost D; de Boer OJ; Van Amstel P; Bakker PJ; Leenstra S; Bosch DA
    Br J Cancer; 1996 Jul; 74(2):187-93. PubMed ID: 8688320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of idarubicin.
    Robert J
    Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral idarubicin--an anthracycline derivative with unique properties.
    Goebel M
    Ann Hematol; 1993 Jan; 66(1):33-43. PubMed ID: 8431520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of mdr1 gene in human breast primary tumors and metastases.
    Hennequin E; Delvincourt C; Pourny C; Jardillier JC
    Breast Cancer Res Treat; 1993; 26(3):267-74. PubMed ID: 8251651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines.
    Petrini M; Mattii L; Valentini P; Sabbatini AR; Grassi B; Grandi M
    Ann Hematol; 1993 Nov; 67(5):227-30. PubMed ID: 8241346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.
    Schott B; Londos-Gagliardi D; Ries C; Huet S; Robert J
    J Cancer Res Clin Oncol; 1993; 119(9):527-32. PubMed ID: 8100823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical idarubicin--a phase-I study.
    Schultze-Seemann W; Mross K; Burk K; Sommerkamp H
    Urol Res; 1994; 22(2):99-104. PubMed ID: 7974920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
    Kuffel MJ; Ames MM
    Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.
    Bogush T; Smirnova G; Shubina I; Syrkin A; Robert J
    Cancer Chemother Pharmacol; 1995; 35(6):501-5. PubMed ID: 7533670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.
    Schott B; Vrignaud P; Ries C; Robert J; Londos-Gagliardi D
    Br J Cancer; 1990 Apr; 61(4):543-7. PubMed ID: 2331441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.